4-Fluoro-2-iodobenzoic acid | CAS:56096-89-0

We serve 4-Fluoro-2-iodobenzoic acid CAS:56096-89-0 to global customers since 2007, Pls send inquiry to info@nbinno.com or visit www.nbinno.com our official website should you have any interests. This site is for information only.
4-Fluoro-2-iodobenzoic acid

Chemical Name:4-Fluoro-2-iodobenzoic acid
CAS.NO:56096-89-0
Synonyms:4-Fluoro-2-iodobenzoic acid
 
Physical and Chemical Properties:
Density 2.1±0.1 g/cm3
Boiling Point 309.4±27.0 °C at 760 mmHg
Melting Point 140-147ºC
Molecular Formula C7H4FIO2
Molecular Weight 266.008
Flash Point 140.9±23.7 °C
Vapour Pressure 0.0±0.7 mmHg at 25°C
Index of Refraction 1.638
 
Specification:
Appearance:Light yellow powder
Assay:≥98.0%
 
Packing:25 kg/drum, can also be packaged according to customer requirements
Storage:Store in a cool, ventilated place
Application:Intermediate of Organic synthesis.



Contact us for information like 4-Fluoro-2-iodobenzoic acid chemical properties,Structure,melting point,boiling point,density,molecular formula,molecular weight,4-Fluoro-2-iodobenzoic acid physical properties,toxicity information,customs codes,safety, risk, hazard and MSDS, CAS,cas number,4-Fluoro-2-iodobenzoic acid Use and application,4-Fluoro-2-iodobenzoic acid technical grade,usp/ep/jp grade.


Related News: At present, China’s bulk drug industry is mainly focused on bulk drug substances, and there is huge room for development in terms of specialty drug substances and patented drug substances.4-methyl-3-nitro-1H-pyridin-2-one manufacturer At present, China’s bulk drug industry is mainly focused on bulk drug substances, and there is huge room for development in terms of specialty drug substances and patented drug substances.1,2,3-Triacetyl-5-deoxy-D-ribose supplier Onconova Therapeutics, Inc. is a Phase 3-stage biopharmaceutical company focused on discovering and developing novel small molecule drug candidates to treat cancer, with an initial focus on Myelodysplastic Syndromes (MDS).1-(4-Bromophenyl)naphthalene vendor Matthew Cheung, Hong Kong’s No. 2 official, appealed to medical workers to reconsider. “At this critical moment, I believe the general public would count on medical personnel to fight against the epidemic together, in the spirit of professionalism,” he wrote in a blog post on Sunday.Due to the time-consuming process of EIA approval and EIA acceptance for newly-built projects, and environmental protection supervision policies are becoming increasingly tight, the company strives to improve capacity utilization through reasonable equipment layout when designing and constructing capacity.